NEWS: 公告在东京证券交易所JASDAQ标准市场新上市



Closed System Drug Transfer Devices to 2026

出版商 Greystone Research Associates 商品编码 985625
出版日期 内容资讯 英文
商品交期: 最快1-2个工作天内
封闭式药物传输系统(CSTD):~2026年 Closed System Drug Transfer Devices to 2026
出版日期: 2021年02月02日内容资讯: 英文




  • 封闭药物转移系统(CSTD)的预测
  • 执行摘要
  • 癌症治疗趋势
  • 癌症治疗的演变
  • 化学疗法
  • 免疫疗法
  • 细胞毒性药物的作用演变
  • 重组药物生态系统
  • CSTD市场动态
  • 药房
  • POC(护理点)
  • 技术因素
  • CSDT竞争情况
  • 风险与机遇
  • 细胞毒性药物市场
  • 不断变化的处方因素
  • 封闭式药物转移的设计因素
  • 癌症药物的安全性
  • 材料选择问题
  • 毒品重建
  • 癌症治疗的用途和数量
  • 药物特异性剂量变化和个体剂量
  • CSDT设备性能因素
  • 围攻
  • 测试协议
  • CSDT设备:主要市场领域
  • 教学医院
  • 社区/社区医院
  • 癌症中心/诊所
  • 封闭式药物转移:设备评估
  • 市场评估和预测
  • 区域数据
  • 公司简介
Product Code: CST929F

Technology-driven Patient & Caregiver Safety

The administration of drugs deemed hazardous to humans has been receiving increasing amounts of scrutiny in recent years as the dangers of these substances become more clearly understood. For caregivers and their patients, the therapeutic area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that - in spite of promising new drugs based on therapeutic antibodies - continues to rely heavily on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers. Regulatory and industry efforts to create standards and procedures designed to protect workers and patients from accidental and incidental exposure to cytotoxics are being driven by data that suggests a causal link between exposure and health issues.

What You Will Learn:

  • What are the key segments and addressable markets that comprise the market for cytotoxic drug delivery?
  • What are the major therapeutic demand drivers for cytotoxic drug therapeutics?
  • What are the design factors and technologies that are being used in commercial and development-stage closed drug transfer systems?
  • What is the market share and product position in the market and what will it look like in 2026?
  • Who are the companies behind the current generation of cytotoxic transfer devices and what are their business models?
  • What is the role of pharma-device alliances and design partnerships in the commercialization and market access of new and emerging closed system drug transfer devices?
  • What is the impact of economic, technology, and regulatory factors on CSDT device demand?

Table of Contents

  • Closed System Drug Transfer Devices to 2026
  • Executive Summary
  • Oncology Drug Trends
  • The Evolution in Oncology Therapeutics
  • Chemotherapy
  • Immunotherapy
  • The Evolving Role of Cytotoxic Drugs
  • The Recombinant Drug Ecosystem
  • CSTD Market Dynamics
  • Pharmacy
  • Point-of-Care
  • Technology Factors
  • CSDT Competitive Landscape
  • Risks and Opportunities
  • The Market for Cytotoxic Drugs
  • Evolving Prescribing Factors
  • Closed System Drug Transfer Design Factors
  • Oncology Therapeutics Medication Safety
  • Material Selection Issues
  • Drug Reconstitution
  • Oncology Drug Administration and Dosing
  • Drug-Specific Dosing Modification and Individualized Dosing
  • CSDT Device Performance Factors
  • Vapor Containment
  • Testing Protocols
  • CSDT Devices - Key Market Segments
  • Teaching Hospitals
  • Regional/Community Hospitals
  • Oncology Centers/Clinics
  • Closed Drug Transfer - Device Assessments
  • Market Assessments and Forecasts
  • Geographic Data
  • Company Profiles